Retatrutide Weight Loss Breakthrough: Triple-Hormone Drug Matches Surgery Results

retatrutide weight loss triple agonist obesity drug editorial cover

Eli Lilly’s retatrutide weight loss trial achieved up to 30.3% body weight reduction, matching bariatric surgery. Phase 3 TRIUMPH-1 data, mechanism, and access analysis.

WHO Sounds Alarm: Attacks on Iran’s Health Infrastructure Trigger Global Emergency

H5N1 bird flu 2026 — pandemic risk warning, virus spreading across species, WHO and CDC alert

H5N1 bird flu 2026 spreads across more species than ever. First H5N5 human case confirmed. No vaccine works. Scientists warn of a pandemic worse than COVID-19.

WHO Sounds Alarm: Attacks on Iran’s Health Infrastructure Trigger Global Emergency

who-iran-health-infrastructure-attacks

WHO warns of global emergency as over 20 attacks on Iran’s health infrastructure cripple hospitals and labs. Read the full report.

WHO Chief Warns of Nuclear Disaster After Fourth Strike on Iran’s Bushehr Plant

WHO chief Tedros Adhanom Ghebreyesus warns of nuclear disaster after fourth strike on Iran's Bushehr nuclear power plant

WHO chief Tedros warns that attacks on Iran’s Bushehr nuclear plant could trigger a nuclear disaster with health impacts that would devastate generations.

FDA Approves Eli Lilly’s GLP-1 Weight Loss Pill Foundayo, Igniting a New Battle in the Obesity Market

GLP-1 weight loss pill bottle Foundayo on a kitchen table

FDA approves Eli Lilly’s GLP-1 weight loss pill Foundayo. A once-daily oral drug that could transform obesity care. Read analysis.